News
![](/sites/default/files/styles/full_article/public/2021-12/Androgen%20Receptor%20Study.jpeg?itok=A9Kj23jv)
Stopping the cycle: combination therapy reduces growth of androgen-receptor positive breast and prostate cancers
Treating androgen receptor (AR)-positive prostate and breast cancer with two drugs that block AR and cyclin-dependent kinase activity slows proliferation of cancer cells.
![](/sites/default/files/styles/full_article/public/2020-12/Leung%20et%20al.%281%29.png?itok=S3R1fd6N)
An optimized tool for the development of novel therapies for treatment-resistant prostate cancer
The development of novel therapeutics for the treatment of chemotherapy-resistant prostate cancer relies on disease models that accurately mimic the progression of human disease. When transferred into mice, a particular cell line does just that, allowing researchers to test the efficacy of potential drugs. But studies have shown that the cell line suffers from a lack of reproducibility and that an improved model of treatment-resistant prostate cancer is needed.
![](/sites/default/files/styles/full_article/public/2020-08/Radiotherapy%20and%20AR%20copy%281%29.png?itok=_9GLrX2t)
Cancer drug synergizes with radiation therapy in treatment-resistant prostate cancer
In a new study published in the journal Cancers, led by GSC Distinguished Scientist Dr. Marianne Sadar, researchers have demonstrated a potential synergistic treatment strategy for resistant cases of prostate cancer.
![](/sites/default/files/styles/full_article/public/2020-03/DSC05414_0.jpg?itok=aeBENKua)
From fighting marine contaminants to fishing for cancer treatments from marine sponges: how a GSC biochemist made a drug discovery breakthrough
Dr. Marianne Sadar is not one to back down from a challenge. So even when told it wasn’t possible, she did something no one else dared to try.